Jiangsu GDK Biotechnology Co., Ltd. (688670)
Market Closed
11 Aug, 06:57
SSE SSE Primary ¥
15. 59
-0.23
-1.4539%
¥
1.52B Market Cap
- P/E Ratio
0.8% Div Yield
1.28M Volume
- Eps
¥ 15.82
Previous Close Want to track 688670 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
688670 closed today lower at ¥15.59, a decrease of -1.4539% from yesterday's close, completing a monthly decrease of -7.9693% or -¥1.35. Over the past 12 months, 688670 stock lost -22.707%.
688670 is not paying dividends to its shareholders.
The last earnings report, released on Apr 17, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Jiangsu GDK Biotechnology Co., Ltd. has completed 1 stock splits, with the recent split occurring on May 26, 2023.
The company's stock is traded on one exchange.
688670 Chart
People also search for
Jiangsu GDK Biotechnology Co., Ltd. (688670) FAQ
What is the stock price today?
The current price is ¥15.59.
On which exchange is it traded?
Jiangsu GDK Biotechnology Co., Ltd. is listed on SSE.
What is its stock symbol?
The ticker symbol is 688670.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.8%.
What is its market cap?
As of today, the market cap is 1.52B.
Has Jiangsu GDK Biotechnology Co., Ltd. ever had a stock split?
Jiangsu GDK Biotechnology Co., Ltd. had 1 splits and the recent split was on May 26, 2023.
Jiangsu GDK Biotechnology Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Jun Yu CEO | SSE Exchange | CNE100004NR4 ISIN |
| CN Country | 451 Employees | 26 May 2023 Last Dividend | 26 May 2023 Last Split | - IPO Date |
Overview
Jiangsu Gdk Biological Technology Co., Ltd is a prominent entity in the pharmaceutical sector, focusing its efforts on the scientific research, production, operation, and service facets concerning human vaccines. Founded in the year 2008 and stationed in Taizhou, China, the company has dedicated itself to the noble cause of preventing infectious diseases through the development of effective vaccines. Its operational ethos is pivoted on harnessing scientific innovations to bolster human health security against various infectious diseases.
Products and Services
- Quadrivalent Influenza Virus Split Vaccines: A cornerstone product developed to provide immunity against four strains of influenza, thereby safeguarding individuals during flu seasons through a broad coverage approach.
- Influenza: Through its research and development wing, Jiangsu Gdk Biological Technology Co., Ltd has amplified its vaccine series to include vaccines against influenza, focusing on minimizing the disease's impact through preventive measures.
- Rabies: The company extends its vaccine portfolio to include prevention against rabies, a critical vaccine given the fatal nature of the disease if not treated promptly and effectively.
- Chickenpox: With the aim of reducing the incidence of chickenpox, a common yet potentially serious illness, the company offers vaccines that ensure immunity and safeguard particularly vulnerable populations like children.
- Herpes Zoster (Shingles): Recognizing the significant discomfort and potential complications associated with herpes zoster, Jiangsu Gdk Biological Technology Co., Ltd provides vaccines to prevent this condition, primarily in older adults.
- Pneumonia: Addressing one of the principal infectious diseases, the company also produces vaccines for the prevention of pneumonia, targeting multiple age groups to reduce the burden of this disease.
Contact Information
Address: 12 Yujin Road, Taizhou, China, 225300
Phone: 86 523 8620 0906
Website: https://www.gdkbio.com
